ReviewGynecologic oncology2016
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Review in Gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Immunogenic Cell Death-relevant Molecular Patterns, Prognostic Genes, and Implications for Immunotherapy in Ovarian Cancer.Current medicinal chemistry · 2026Article
- Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.Frontiers in cell and developmental biology · 2025Review
- Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer.Frontiers in pharmacology · 2023Article
- PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed.Frontiers in oncology · 2022Review
- Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.Journal for immunotherapy of cancer · 2021Article
- Comprehensive analysis of the prognostic value and immune function of theAmerican journal of translational research · 2021Article
- Immunotherapy Advances for Epithelial Ovarian Cancer.Cancers · 2020Review
- Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.BMC cancer · 2020Article
- Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies.Infection and drug resistance · 2020Review
- Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.Gynecologic oncology · 2019Article
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2019Article
- Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.Gynecologic oncology · 2019Article
- Epigenetic therapy for ovarian cancer: promise and progress.Clinical epigenetics · 2019Review
- Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer.JCO precision oncology · 2019Article
- Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.Current oncology reports · 2018Review
- The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.Frontiers in endocrinology · 2018Article
- Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites.Molecular therapy oncolytics · 2017Article
- AHeliyon · 2017Article
- Update on immune checkpoint inhibitors in gynecological cancers.Journal of gynecologic oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
During the past decade significant progress in the understanding of stimulatory and inhibitory signaling pathways in immune cells has reinvigorated the field of immuno-oncology. In this review we outline the current immunotherapy based approaches for the treatment of gynecological cancers, and focus on the emerging clinical data on immune checkpoint inhibitors, adoptive cell therapies, and vaccines. It is anticipated that in the coming years biomarker-guided clinical trials, will provide for a better understanding of the mechanisms of response and resistance to immunotherapy, and guide combination treatment strategies that will extend the benefit from immunotherapy to patients with gynecologic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.